RxDoctor Payments Data

Egede Aitsebaomo, MD

Cardiovascular Disease · Sayre, PANPI 1376620682

Payments from drug & device makers

$318in general payments, 2019–2025

Across 10 payments — averaging $31.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$124
  • Abbott$68
  • Amgen$65
  • Akcea Therapeutics, Inc.$27
  • Alnylam Pharmaceuticals Inc.$21
  • Bardy Diagnostics, Inc.$13

What the payments were for

  • Food & beverage$318100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca1$124
Abbott3$68
Amgen3$65
Akcea Therapeutics, Inc.1$27
Alnylam Pharmaceuticals Inc.1$21
Bardy Diagnostics, Inc.1$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$318 in reported general payments places this provider in the 20th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

See all cardiovascular disease providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$159,507
Medicare patients
1,426
Services billed
2,860

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban139$194,713
JardianceEmpagliflozin138$193,349
XareltoRivaroxaban69$74,572
EntrestoSacubitril/Valsartan68$65,160
Repatha SureclickEvolocumab41$30,043
VascepaIcosapent Ethyl25$22,447
Repatha SyringeEvolocumab19$17,987
Dofetilide35$14,930
FarxigaDapagliflozin Propanediol18$14,659
Praluent PenAlirocumab12$11,381
BrilintaTicagrelor13$9,043
Metoprolol Succinate282$4,690
Eplerenone42$3,426
Rosuvastatin Calcium188$2,838
Clonidine13$2,160

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Brilinta$124$23,70231 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 1,250 cardiovascular disease providers in Pennsylvania.

Other cardiovascular disease in Sayre

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →